ArticleEcancermedicalscience2017
Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma.
Article in Ecancermedicalscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Exploration of risk factors for the occurrence and recurrence of papillary thyroid carcinoma with Hashimoto's thyroiditis based on next-generation sequencing.Diagnostic pathology · 2025Article
- A review of complex hormone regulation in thyroid cancer: novel insights beyond the hypothalamus-pituitary-thyroid axis.Frontiers in endocrinology · 2024Review
- Puberty and sex in pediatric thyroid cancer: could expression of estrogen and progesterone receptors affect prognosis?European thyroid journal · 2022Article
- Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors.Analytical cellular pathology (Amsterdam) · 2022Article
- Thyroid diseases and second to fourth digit ratio in Polish adults.Scientific reports · 2021Article
- Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases.International journal of molecular sciences · 2021Review
- Incidence of Thyroid Cancer in Italian Contaminated Sites.International journal of environmental research and public health · 2020Article
- Papillary Thyroid Cancer-Promoting Activities of Combined Oral Contraceptive Components.Galen medical journal · 2020Article
- Distribution and Prognostic Significance of Estrogen ReceptorJournal of thyroid research · 2020Article
- Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.Pathology oncology research : POR · 2020Review
- Causal associations of autoimmune thyroiditis and papillary thyroid carcinoma: mRNA expression of selected nuclear receptors and other molecular targets.Oncology letters · 2019Article
- Rare Occurrence of Incidental Finding of Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features in Hürthle Cell Adenoma.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2018Article
- Reduced expression of oestrogen receptor-β is associated with tumour invasion and metastasis in oestrogen receptor-α-negative human papillary thyroid carcinoma.International journal of experimental pathology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC) is the most common thyroid cancer with multiple risk factors including exposure to ionising radiation. Oestrogens contribute to papillary carcinoma development by promoting cell proliferation and invasion of mutated epithelial follicular cells. The present study aimed to assess ER-α and PR expression in PTC and to correlate their expression with the clinicopathological parameters in this cancer. This study included 62 primary and six metastatic papillary thyroid carcinoma cases. Nineteen and 38.7% of primary PTC cases showed positive nuclear expression for ER and PR, respectively. Metastatic cases showed 66.7% positive ER expression and all were negative for PR. Oestrogen receptor expression showed significant higher positivity in metastatic compared to primary PTC (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.